“I'm basically highlighting some of the data that's currently out there, but more importantly, some of the data that [are] just emerging,” says Steven A. Kaplan, MD.
In this video, Steven A. Kaplan, MD, shares talking points from his presentation at the 2021 LUGPA annual meeting. Kaplan is a professor of urology at the Icahn School of Medicine and director of the Men’s Wellness Program at Mount Sinai, New York, New York.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.